Kamada Stock Sees Q3 Earnings Estimate Decreased at Sidoti

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at Sidoti dropped their Q3 2026 EPS estimates for shares of Kamada in a research report issued on Friday, September 25th. Sidoti analyst J. Sidoti now expects that the biotechnology company will earn $0.10 per share for the quarter, down from their previous forecast of $0.12. The consensus estimate for Kamada’s current full-year earnings is $0.48 per share. Sidoti also issued estimates for Kamada’s Q4 2026 earnings at $0.09 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.12 EPS, Q1 2028 earnings at $0.11 EPS, Q2 2028 earnings at $0.12 EPS and FY2028 earnings at $0.50 EPS.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%.

Several other research firms have also commented on KMDA. William Blair set a $15.00 price target on Kamada in a research report on Tuesday, July 21st. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research note on Tuesday, September 22nd. Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, UBS Group restated a “buy” rating and issued a $15.00 price target on shares of Kamada in a report on Friday, September 18th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kamada currently has a consensus rating of “Buy” and an average price target of $13.50.

Kamada Stock Up 0.8%

Kamada stock opened at $8.69 on Monday. The business has a fifty day moving average of $7.93 and a two-hundred day moving average of $7.89. The firm has a market cap of $499.76 million, a P/E ratio of 22.87, a P/E/G ratio of 0.72 and a beta of 0.88. Kamada has a twelve month low of $6.50 and a twelve month high of $9.35.

Kamada Cuts Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, September 17th. Investors of record on Thursday, August 27th were given a dividend of $0.17 per share. The ex-dividend date of this dividend was Thursday, August 27th. This represents a yield of 206.0%. This is a decrease from Kamada’s previous annual dividend of $0.25. Kamada’s dividend payout ratio is currently 34.21%.

Hedge Funds Weigh In On Kamada

An institutional investor recently raised its position in Kamada stock. Aristides Capital LLC increased its stake in Kamada Ltd. (NASDAQ:KMDA) by 4.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,491 shares of the biotechnology company’s stock after purchasing an additional 1,476 shares during the period. Aristides Capital LLC owned 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.